Business Description
Akebia Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US00972D1054
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.98 | |||||
Equity-to-Asset | -0.12 | |||||
Debt-to-Equity | -1.57 | |||||
Debt-to-EBITDA | 28.03 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.99 | |||||
Beneish M-Score | -2.03 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -21.3 | |||||
3-Year EBITDA Growth Rate | 73.9 | |||||
3-Year EPS without NRI Growth Rate | 53.7 | |||||
3-Year FCF Growth Rate | 46.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.81 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.7 | |||||
9-Day RSI | 36.75 | |||||
14-Day RSI | 37 | |||||
6-1 Month Momentum % | 29.6 | |||||
12-1 Month Momentum % | 12.84 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.7 | |||||
Quick Ratio | 1.31 | |||||
Cash Ratio | 0.63 | |||||
Days Inventory | 112.65 | |||||
Days Sales Outstanding | 49.07 | |||||
Days Payable | 66.7 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.5 | |||||
Shareholder Yield % | 11.74 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 64.98 | |||||
Operating Margin % | -18.94 | |||||
Net Margin % | -22.98 | |||||
FCF Margin % | -13.5 | |||||
ROA % | -17.45 | |||||
ROIC % | -19.12 | |||||
ROC (Joel Greenblatt) % | -149.36 | |||||
ROCE % | -22.22 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.15 | |||||
EV-to-EBIT | -6.59 | |||||
EV-to-EBITDA | 155.48 | |||||
EV-to-Revenue | 1.27 | |||||
EV-to-Forward-Revenue | 1.24 | |||||
EV-to-FCF | -9.4 | |||||
Earnings Yield (Greenblatt) % | -15.17 | |||||
FCF Yield % | -10.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Akebia Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 172.962 | ||
EPS (TTM) (€) | -0.21 | ||
Beta | 1.62 | ||
Volatility % | 99.72 | ||
14-Day RSI | 37 | ||
14-Day ATR (€) | 0.044591 | ||
20-Day SMA (€) | 1.070825 | ||
12-1 Month Momentum % | 12.84 | ||
52-Week Range (€) | 0.741 - 2.85 | ||
Shares Outstanding (Mil) | 209.6 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Akebia Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Akebia Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Akebia Therapeutics Inc Frequently Asked Questions
What is Akebia Therapeutics Inc(FRA:AX9)'s stock price today?
When is next earnings date of Akebia Therapeutics Inc(FRA:AX9)?
Does Akebia Therapeutics Inc(FRA:AX9) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |